Details

Autor(en) / Beteiligte

• Wu, Xiaoxiao
• Yang, Junhao
• Wu, Juanjie
• Yang, Xuyan

Titel

Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome in systemic lupus erythematosus

Ist Teil von

• Biomedicine & pharmacotherapy, 2024-03, Vol.172, p.116261-116261, Article 116261

Ort / Verlag

France: Elsevier Masson SAS

Erscheinungsjahr

2024

Link zum Volltext

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with a pathogenesis that remains incompletely understood, resulting in limited treatment options. MCC950, a highly specific NLRP3 inflammasome inhibitor, effectively suppresses the activation of NLRP3, thus reducing the production of caspase-1, the pro-inflammatory cytokines IL-1β and IL-18. This review highlights the pivotal role of NLRP3 inflammasome activation pathways in the pathogenesis of SLE and discusses the potential therapeutic application of MCC950 in SLE. Notably, it comprehensively elucidates the mechanism of MCC950 targeting the NLRP3 pathway in SLE treatment, outlining its potential role in regulating autophagy and necroptosis. The insights gained contribute to a deeper understanding of the value of MCC950 in SLE therapy, serving as a robust foundation for further research and potential clinical applications. [Display omitted] •Summarized the activation of NLRP3 in systemic lupus erythematosus.•Outlined the potential mechanisms of MCC950 in regulating NLRP3.•Proposed a novel therapy using MCC950 for systemic lupus erythematosus treatment.